PF-Atlas › Clinical Trials › NCT02682511

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis or SSc-associated Pulmonary Arterial Hypertension

Oral Ifetroban · Phase 2

Registry ID
NCT02682511
Phase
Phase 2
Status
Active, not recruiting
Drug / intervention
Oral Ifetroban
Sponsor
Cumberland Pharmaceuticals
Start
2017-01
Enrollment
34
Locations
13

About this trial

The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).

View NCT02682511 on ClinicalTrials.gov →

Explore related

All Oral Ifetroban trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT02682511 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.